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Abstract
 Alpha-1-antitrypsin is a potent antiprotease playing an important role in maintaining protease-antiprotease 
balance. It protects the structures of extracellular matrix against destruction by proteolytic enzymes. Loss of 
elasticity occurs when increased protease activity is accompanied by qualitative impairment or reduced con-
centrations of antiproteases. Alpha-1-antitrypsin deficiency is a risk factor for obstructive lung disease, including 
emphysema, liver and kidney disorders and, less often, follicular panniculitis, granulomatosis with polyangiitis 
(previously Wegener’s granulomatosis). Literature also emphasises the role of AAT in the development of aortic 
aneurysms, and results of biochemical studies support this theory. Aortic aneurysm is an important clinical 
problem, unceasingly associated with high mortality. For this reason, it is exceptionally important to identify its 
risk factors. Studies on the relationship between AAT and development of AAA (abdominal aortic aneurysm) 
have been conducted since the 1990s. Due to the development in molecular diagnostic techniques, new reports 
on the topic appeared over the last decade.
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Introduction
Abdominal aortic aneurysm (AAA) is defined as 
widening of the aorta by at least 50% compared to its 
normal diameter. Another definition describes AAA as 
distention of the aorta by > 3 cm. 
It usually occurs after the age of 55 and is 4–8 times 
more common in men than in women, with its preva-
lence estimated at 4–7.6%. 
Aneurysm is a symptom of a defect in the intima me-
dia of the vascular wall, the main component of which is 
elastin. In a normal aorta, the number of elastin layers is 
significantly reduced in the subrenal region, which may 
explain the most frequent localisation of aneurysms. 
Elastin is not synthesised in an adult aorta and its half-life 
is estimated at 50–70 years. The process of tissue aging 
alone does not lead to pathological arterial dilatation, it 
occurs as a result of uncontrolled destruction by prote-
olytic enzymes. Another mechanism involves mutations 
leading to production of abnormal connective tissue 
proteins that act as a scaffold for collagen and elastin, 
e.g. fibrilin-1 mutation in Marfan syndrome. 
Pathogenesis of aneurysm-like lesions is difficult to 
establish, as they often coexist with atherosclerosis [1]. 
Proteolytic processes, augmented by chronic inflam-
mation, antiprotease deficiency, and haemostasis, 
play a significant role in their development. The main 
proteolytic enzyme of fibrinolysis — plasmin, activates 
extracellular matrix metalloproteinases (MMP), which 
break down aortic wall components. 
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Histopathological sections show fragmentation of 
the elastin fibres, increased metalloproteinase activity, 
and inflammatory reaction in the tunica intima and ad-
ventitia [2–4]. The above-described data demonstrate 
the complexity of this issue and indicate the need for 
further investigation. 
There are well-established factors that influence 
the development of AAA, such as: atherosclerosis, 
smoking, COPD, arterial hypertension, age > 50 years, 
and genetic predispositions. Much less is known about 
phenomena leading to progression of aortic lesions: in-
flammation, remodelling of connective tissue scaffolding 
and oxidative stress, as well as protease-antiprotease 
imbalance and the role of alpha-1-antitrypsin. The im-
pact of excessive destruction or insufficient rebuilding 
of the extracellular matrix in response to inflammation 
among patients with aneurysms remains speculative. 
 Significance of AAT
Excessive proteolysis causes destruction of elastic 
and collagen fibres, resulting in vascular wall remod-
elling. Disruption of protease-antiprotease balance 
occurs when increased activity of proteolytic enzymes 
is accompanied by quantitative or qualitative deficiency 
of antiproteases [5]. 
Neutrophil elastase is the main factor responsible 
for increased proteolysis under deficiency of alpha-1-an-
titrypsin (AAT), the strongest protease inhibitor [6].
Alpha-1-antitrypsin, also known in the literature 
as alpha-1-antiprotease, owes its name to a historical 
hypothesis indicating trypsin (a serine protease) as 
its main antagonist. It is currently known, that the 
scope of AAT action is significantly broader. Its phys-
iological activity is based on antiprotease properties 
against proteolytic enzymes, especially neutrophil 
elastase, as well as proteinase 3, myeloperoxidase, 
cathepsin G, serine proteases (tripsin, kallikrein 7 
and 14, urokinase, granzyme B, triptase, chymase, 
matriptase), cysteine proteases (caspase 1 and 3, 
calpain I) and metalloproteinase ADAM-17 (TACE, 
tumour necrosis factor-alpha-converting enzyme) [7]. 
Alpha-1-antitrypsin protein is coded by the SERPINA 
1 gene located on the long arm of chromosome 14 
(4q32.1). It is highly polymorphic and the multitude of 
mutations results in a significant number of variants of 
the product (i.e. AAT). Over 130 of them have been 
identified to date. Normal, fully functional AAT protein 
is produced by variant M of the SERPINA 1 gene. Thus, 
normal genotype, occurrence of two proper M alleles 
is designated as PiMM. PiZ and PiS variants are most 
common in the Caucasian population. Severe inherited 
AAT deficiency occurs among individuals homozygous 
for PiZZ system, with heterozygous PiSZ system, 
or persons with null mutation, which determines a total 
lack of AAT production (PiNull/Null, PiZ/Null) [8]. It 
is thought, that severe homozygotic AAT deficiency 
(PiZZ) in Europe is more common in Scandinavian 
countries (allele frequency 2.3%) than in the south 
of the continent (allele frequency 1.0%) — 1 in 4727 
Caucasian neonates on average. Poland is one of the 
few European countries that does not have full data 
on the prevalence of AAD [9–17]. 
It has been possible to perform full diagnostics of 
alpha-1-deficiency in Poland since 2010. Also, National 
Registry of Patients with AAT Deficiency is in opera-
tion [18]. 
Relationship between AAT protein  
and development of AAA
The occurrence of familial cases and greater pre-
dilection for the disorder among men point to genetic 
background of AAA [19, 20]. Biochemical data support 
the theory of excessive extracellular matrix proteolysis. 
Increased activity of neutrophil elastase, an imbalance 
between AAT antiprotease and neutrophil elastase, 
was observed among patients with abdominal aortic 
aneurysms. However, initial reports on reduced AAT 
protein concentrations were not unequivocally con-
firmed in later studies [21, 22]. 
The first reports come from 1990, when Cohen 
et al. [23] showed more frequent occurrence of PiMZ 
AAT phenotype among patients, who developed ab-
dominal aortic aneurysm. Also, the study by Schardey 
et al. [24] demonstrated greater prevalence of a rare 
PiMV phenotype. The PiV allele is exceptionally rare 
and its biological activity has not been fully determined 
to date. Pini et al. [25] conducted molecular diagnostics 
of AAT deficiency among 138 patients with AAA. Pres-
ence of deficient alleles was confirmed in 20 of them, 
including 16 PiMS, 1 PiSS, 1 PiMZ. A rare variant of 
AAT was also identified in two patients. The authors 
compared their results with data estimates for Italian 
population, demonstrating significantly more frequent 
occurrence of deficient PiS alleles in the AAA group 
(7.8% vs. 2.2%, p < 0.001), as well as lack of significant 
differences for PiZ (1.1% vs. 1.3%, p>0.05). According 
to the authors, noted differences point to the role of 
AATD in the pathogenesis of AAA. 
Elzouki and Eriksson [26] also suggested a possible 
role of PiS in this disorder, presenting a case of a patient 
with AAA and deficit PiSZ genotype. Concurrently, no 
relationship was demonstrated between severe AAT 
deficiency caused by PiZZ genotype and increased risk 
of AAA development. Autopsy of 30 individuals ho-
mozygous for PiZZ and 120 patients with normal PiMM 
variant failed to corroborate statistically  significant 
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dependence between AAA development and PiZZ 
genotype (p=0.027). Results of studies by Ramsbottom 
et al. published in the same year demonstrated signif-
icantly more frequent occurrence of PiMZ and PiZZ 
genotypes among patients diagnosed with abdominal 
aortic aneurysm [27]. Concordant results of Elzouki 
and Eriksson [26], Ramsbottom [27], and Pini [25] indi-
cate the involvement of PiS variant in the pathogenesis 
of AAA in contrast to the results obtained by Cohen 
et al. [23], who observed such relationship for PiZ only. 
Over the last decade, intense studies were con-
ducted devoted to the analysis of human proteome, 
including investigations focused on identification of 
differences in protein profiles among patients with 
AAA compared to healthy subjects. Significantly higher 
expression of AAT was demonstrated in comparison 
with the control group (p<0.05) [28]. Increased serum 
AAT in patients with AAA may indicate the necessity 
for inhibition of proteases responsible for change in the 
structure of vascular wall.
Biological activity of AAT protein is also an important 
issue. It is determined not only by its concentrations 
in blood or tissues, but also by its structure. The 
above-mentioned studies analysed mainly the quantita-
tive aspect of the problem. Besides AAT, 24 other pro-
teins were identified. Since the control group consisted 
of patients without atherosclerosis, selected proteins 
may be associated with evolution of atherosclerotic 
plaques. Moreover, due to AAT being an acute-phase 
protein, the scope of its function as a biomarker in 
vascular pathology requires further investigation. 
Since patients with AATD are at an increased risk 
of vascular disease, studies on vessel elasticity are also 
of interest. Booms et al. [29] observed a tendency to-
wards significantly lower blood pressure among men 
with AATD compared to those presenting PiMM phe-
notype, which, according to authors, has a strong causal 
relationship with reduced arterial elasticity. Absence of 
a similar relationship in the group of studied females 
seems to corroborate this hypothesis in the context of 
known influence of estrogens on vascular wall tension. 
However, Elzouki et al. [30], who examined pulsatile 
change in vessel diameter based on ultrasound exam-
ination together with blood pressure measurements, 
demonstrated no differences between men heterozy-
gous for PiZ and the control group with PiMM. On the 
other hand, the study confirmed less frequent occur-
rence of ischaemic heart disease among patients with 
AAA and heterozygous variant of PiZ AAT compared 
with AAA and proper AAT structure (p = 0.03). The 
same research team showed also significantly reduced 
elasticity of abdominal aorta among male patients 
homozygous for PiZZ compared to men with PiMM 
(p = 0.025). As in other studies, no such relationships 
were found for females (p = 0.17) [31]. It seems that 
the above-described phenomena may be interpreted 
as early vascular changes, supporting the predilection 
of individuals with AATD for vascular disease.
Analysis of literature from 2003 yielded a weak re-
lationship between AATD and AAA. According to the 
statement of the American Thoracic Society and Eu-
ropean Respiratory Society, AATD does not constitute 
the main genetic determinant for development of AAA, 
although its role in this process has not been completely 
excluded. Results of studies and biochemical back-
ground point to disruption of AAT protein structure 
and function as a possible risk factor for development 
of AAA. Also, joint guidelines by the American Thoracic 
Society and European Respiratory Society emphasise 
the need for further studies on this issue [32]. 
Summary
Growing knowledge of biochemical processes 
and progress in the field of genetics enabled ongoing 
research on the role of abnormal AAT variants in the 
pathogenesis of AAA. Available literature data is in-
conclusive. Proteomic studies demonstrated increased 
expression of AAT protein among patients with AAA 
compared to the profile found in healthy subjects.
Significantly more frequent occurrence of deficient 
AAT phenotypes among patients with AAA has yet not 
been unequivocally corroborated, although some stud-
ies convincingly point to the possible role of impaired 
PiS AAT protein in the pathogenesis of the disorder. 
However, some studies led to discovery of new, pre-
viously unknown variants of AAT protein, showing that 
it is highly polymorphic. Reports of abdominal aortic 
aneurysm development in patients homozygous for 
PiZZ variant of AAT are rare and most likely associated 
with the influence of other factors.
Despite several decades of research, the aetiology 
of AAA remains unclear. Obtained evidence does not 
exclude the role of AAT — one of the most potent anti-
proteases, in the pathogenesis of AAA. Considering the 
properties of AAT and available literature data, further 
research seems reasonable. 
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